PT003 MDI Dose Confirmation Study
Public ClinicalTrials.gov record NCT01349816. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Study identification
- NCT ID
- NCT01349816
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- PT003 Drug
- PT001 Drug
- PT005 Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2011
- Primary completion
- Oct 31, 2011
- Completion
- Oct 31, 2011
- Last update posted
- Apr 26, 2017
2011
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pearl Investigative Site | Rancho Mirage | California | — | — |
| Pearl Investigative Site | Colorado Springs | Colorado | — | — |
| Pearl Investigative Site | Waterbury | Connecticut | — | — |
| Pearl Investigative Site | Clearwater | Florida | — | — |
| Pearl Investigative Site | Pensacola | Florida | — | — |
| Pearl Investigative Site | Stockbridge | Georgia | — | — |
| Pearl Investigative Site | Minneapolis | Minnesota | — | — |
| Pearl Investigative Site | Brooklyn | New York | — | — |
| Pearl Investigative Site | Charlotte | North Carolina | — | — |
| Pearl Investigative Site | Winston-Salem | North Carolina | — | — |
| Pearl Investigative Site | Cincinnati | Ohio | — | — |
| Pearl Investigative Site | Medford | Oregon | — | — |
| Pearl Investigative Site | Spartanburg | South Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01349816, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01349816 live on ClinicalTrials.gov.